ABSTRACT
Dystrophin, the protein product of the Duchenne muscular dystrophy gene, is expressed in brain as well as muscle. The role of dystrophin in the brain is not clear, though one-third of Duchenne muscular dystrophy patients exhibit some degree of mental retardation. We have isolated the genomic region encoding the alternative 5' terminus of dystrophin used in the brain. Primer extension and polymerase chain reaction assays on RNA demonstrate that this region contains an alternative promoter for dystrophin used in the brain. Physical mapping of this region indicates that this brain promoter is located >90 kilobases 5' to the promoter used in muscle and 400 kilobases from exon 2 to which it is spliced. The large physical distance between the promoters, taken together with their known tissue selectivities, suggests that in certain patients a deletion of either dystrophin promoter might give rise to reduced dystrophin expression selective to brain or muscle. We have identified one such individual with specific deletion of the dystrophin muscle promoter, giving rise to Becker muscular dystrophy, and we predict that specific loss of the brain promoter may be one cause of X chromosome-linked mental retardation.
Duchenne muscular dystrophy (DMD) is a relatively common and uniformly lethal inherited disorder. The disease primarily affects muscle, with symptoms of proximal muscle weakness first appearing by age 5 and progressing to respiratory or cardiac failure and death by the third decade. Much insight into the pathophysiology of Duchenne muscle has come from analysis of dystrophin, the protein product of the DMD gene (1) . Dystrophin, a large (427 kDa) protein with amino acid sequence homology to the spectrin family of membrane cytoskeletal proteins (2) (3) (4) , is most abundant in skeletal and cardiac muscle, where it has been localized to the inner face of the plasma membrane (5) (6) (7) (8) . Dystrophin is also found throughout the body in smooth muscle (9) . DMD results from severely reduced amounts of dystrophin, whereas the milder Becker muscular dystrophy results primarily from mutations that generate dystrophin of abnormal molecular weight or quantity (10, 11) . It is hypothesized that dystrophin might serve to stabilize the plasma membrane during muscle fiber contraction and that absence of dystrophin leads to membrane disruption and muscle fiber necrosis (6, 12) . The only nonmuscle tissue that expresses significant levels of dystrophin is the brain (1, 9, 13, 14) .
The presence ofdystrophin in the brain has revived interest in the possible central (1, 9, 13, 14) , making analysis of dystrophin in the brain difficult. Nevertheless, it is known that dystrophin mRNA in the brain contains different sequences at the 5' terminus from that found in muscle, suggesting that dystrophin is transcribed from an alternate promoter or is alternatively spliced in the brain (16, 17) . Low levels of the braintype 5' terminus have been found in muscle, and low levels of the muscle transcript have been observed in the brain (16, 18) . Therefore, the alternative 5' terminal sequences appear to show tissue selectivity rather than strict specificities.
To study the expression of dystrophin in the brain, we isolated genomic sequences encoding the 5' region of dystrophin found in brain transcriptst. We demonstrate that this genomic region contains an alternate promoter for dystrophin in brain, which is located >90 kilobases (kb) upstream of the DXS142 region containing the major muscle promoter (19) . The finding that the DMD gene contains dual promoters, which are widely spaced, suggests that deletion mutations may disrupt expression of one tissue-selective promoter without affecting expression in the other tissue, thus giving rise to novel phenotypes. We have identified one such example in a patient with Becker muscular dystrophy caused by specific deletion of the muscle promoter.
EXPERIMENTAL PROCEDURES
Genomic Cloning and Sequence Analysis. A normal human female genomic library in EMBL3 was screened using a 32P-labeled-polymerase chain reaction (PCR) probe prepared as described (20) . Phage growth, library screening, phage DNA isolation, and subcloning were by routine procedures (21) . DNA sequencing was performed using the Sequenase kit version 2.0 (United States Biochemical).
RNA Analysis. PCR was performed directly on RNA as described (22) . The antisense exon 3 primer was 5'-TAGGTCACTGAAGAGGTTCTCAATATGCTG-3'.
Primer extensions were performed as described (21) complementary to the vector. The resulting product, containing 3 kb of 5' flanking region as a HindIII fragment, was subcloned into a polylinker-containing derivative of pSVO A/L A 5' (23). To allow expression in COS cells, a fragment containing the simian virus 40 enhancer was prepared by PCR of pSV2CAT (24) and subcloned into the Xho I site of the polylinker. The resulting construct, pB-Luc/E, contained 3 kb of 5' flanking sequence from the upstream promoter of dystrophin directing expression of the luciferase reporter gene, with the simian virus 40 enhancer located upstream of the dystrophin sequences. These plasmids and details of their construction are available upon request. Pulsed-Field Gel Analysis. Preparation of DNA in agarose blocks and restriction enzyme digestions were performed as described (25) . Digested DNA was separated in 1% agarose gels in 45 mM Tris borate/1 mM EDTA buffer by using an LKB Pulsaphor unit with either the double inhomogenous field electrodes at 330 V with alternating switching times of 15, 30, and 60 sec at 9°C for 33 hr (Fig. 4 A and B) or with the LKB hexagonal electrode array at 170 V, 10-sec switching, 11°C for 22 hr (Fig. 4 C and D), both as described (25) .
Patient Analysis. PCR analysis was performed on 250 ng of genomic DNA as described (26) . The brain promoter region was amplified by using the primers 5'-GAAGATC-TATATTTTACAACGCAGAAATGTGG-3' and 5'-CTTC-CATGCCAGCTGTTTTTCCTGTCACTC-3'. The muscle promoter region was amplified by using the primers 5'-GAAGATCTAGACAGTGGATACATAACAAATG-CATG-3' and 5'-TTCTCCGAAGGTAATTGCCTCCCA-GATCTGAGTCC-3'. Random-primed probes were prepared by using a DNA labeling kit (Boehringer Mannheim), and filters were hybridized and washed as described (27) . Western blot analysis was performed as described (10) .
RESULTS

Dystrophin Is Transcribed in Brain From an Alternate
Promoter. Previous reports have demonstrated that dystrophin mRNA from brain tissue contained different 5'-terminal sequences from that found in muscle (16, 17) . To determine whether this difference was the result of alternative splicing or differential promoter usage, the genomic region encoding these alternative sequences was isolated. Four independent A phage encompassing 28 kb of genomic sequence were obtained by screening a human genomic library with a probe derived from the 5' terminus of a dystrophin cDNA from human brain. The DNA sequence immediately 5' to this cDNA was determined and is shown in Fig. 1 . To map the 5' terminus of this exon, a series of PCR primers was designed successively further upstream from the known cDNA sequence (P1-P6, Fig. 1 ) and used in combination with an exon 3 antisense primer in PCR reactions on human brain RNA. As shown in Fig. 2A , only the most proximal primer, P6, was able to amplify the proper product from human brain poly(A)+ RNA. As a control, the same set of primers was also used on genomic DNA in combination with an exon 1 antisense primer, and all were able to amplify the proper sized products (Fig. 2B) . Thus, all of these primers are capable of efficient amplification of this template. This suggests that the endogenous dystrophin transcript in the brain initiates or is spliced within the primer P5 site or between the primer P5 and primer P6 sites.
To map the 5' terminus of the dystrophin transcript within this region, primer extension was performed on human brain RNA and on RNA from cells transfected with this putative promoter region directing expression of a luciferase reporter gene. The level of expression of the endogenous gene in brain was below that detectable by primer extension (Fig. 3, lane  3) . However, in RNA from transfected cells, two major and several minor primer extension products are observed (Fig.  3, lane 1) , which are not observed in RNA from untransfected control cells (Fig. 3, lane 2) . The location of these two major transcription initiation sites in the transfected cells is just upstream from the primer P6 site (Fig. 1) . This result is consistent with the observation that brain RNA was amplified with primer P6 but not with primers P1-P5 ( Fig. 2A) , although transcription initiated at the minor upstream site should yield some degree of amplification with primer P5 as well. Thus, our data suggest that the majority of transcription from this region in human brain initiates just upstream of the primer P6 site. The sequence of this region does not contain any strong TATA box motifs (28, 29) , although there is an A+T-rich region centered 26 bases upstream of the major start sites (Fig. 1) .
The Dystrophin Brain Promoter Is Located a Minimum of 90 kb Upstream of the Muscle Promoter and -400 kb Upstream of Exon 2. To determine the genomic order and locations of the alternative dystrophin promoters, pulsed-field gel electrophoresis was performed. The muscle promoter has been previously mapped to Sfi I fragments of -700 and 840 kb, depending upon the DNA methylation state of the cell line used (refs. 30-33, Fig. 4B ). Pulsed-field gel electrophoresis analysis using probes from the brain promoter region revealed an Sfi I fragment of 140 kb (Fig. 4A) pC+pD site. Probe pD, on the 3' side of this Sal I site, recognized a 55-kb Sal I fragment that was reduced to 45 kb by Sfi I digestion (Fig. 4D) , indicating that the brain promoter is 46 kb 5' to the Sfi I site. The muscle promoter probe (p84) hybridizes to a 135-kb Sal I fragment and an extensive series of partial digestion products (Fig. 4B) in common with the brain promoter, indicating that the brain and muscle promoters are located on adjacent Sal I fragments. To localize further the muscle promoter, we constructed a more refined restriction map using Sal I and Sfi I in combination with the enzymes Xho I, BamHI, Bgl I, and Kpn I (data not shown). None of these digestions allowed precise localization of p84 relative to the Sal I sites, but together with information from mapping genomic phage clones of the region, we were able to estimate that the muscle promoter is at least 35 kb downstream ofone Sal I site and 45 kb upstream ofthe other, giving a region of uncertainty of 55 kb. Thus, the muscle promoter is between 90 and 145 kb downstream from the brain promoter.
To link the promoters with the rest of the dystrophin gene, we hybridized the pulsed-field gel electrophoresis filters with a probe specific for exon two of the dystrophin gene, pD38 (a gift from R. Worton, Hospital for Sick Children, Toronto). This probe hybridized to a 390-kb Sfi I fragment in 6697 and GM1202 cells as well as a 700-kb fragment in all cell lines (data not shown). Analysis of double digests revealed that exon 2 is between 28 and 45 kb downstream of the partially digestable Sfi I site at 370 kb on our map (Fig. 5) . This allowed placement of exon 2 relative to the promoters and exons 3-11, which have already been mapped relative to the Sal I and Sfi I sites at 600 and 800 kb, respectively, in Fig. 5 dystrophin are separated by a great distance, taken together with the fact that the majority of DMD mutations are due to intragenic deletions of the dystrophin gene (37) (38) (39) , suggests that some individuals may have loss of one of the dystrophin promoters while maintaining use of the other. Since deletion of the upstream promoter with retention of the downstream promoter would be predicted to result in individuals with severely reduced levels of dystrophin in the brain, but not in muscle, we examined >50 male patients with developmental delay or mental retardation, rather than muscle weakness, for the presence of each promoter. In these preliminary experiments, we have yet to identify a patient with deletion of the upstream "brain" promoter only (Fig. 6A) .
Conversely, deletion of the downstream muscle promoter with retention of the remainder of the gene might be expected to yield patients with decreased abundance of normal-sized dystrophin in muscle. We have previously identified several such patients with reduced amounts of normal-sized dystrophin (11) . To determine if this was a result of deletion or rearrangement of either promoter, we performed PCR analysis on DNA from three male patients by using primers for each promoter. In one patient with reduced levels of fullsized dystrophin (Fig. 6C) , the downstream "muscle" promoter could not be amplified from peripheral blood leukocyte DNA (Fig. 6A) . Southern blot analysis using probes that recognize each promoter, as well as a probe for exon 2, confirmed that this patient had a deletion of the downstream promoter while retaining the flanking brain promoter and exon 2 (Fig. 6B) . PCR analysis of DNA obtained from the muscle biopsy also did not detect the muscle promoter, making it unlikely that the reduced levels of dystrophin were due to somatic mosaicism in this individual. This 10-year-old patient has minimal muscle weakness consistent with mild Becker muscular dystrophy and is intellectually normal. Although it is possible that deletion of the muscle promoter may lead to different phenotypes in other individuals, we have not found specific deletion of the muscle promoter in any other case of DMD, Becker muscular dystrophy, or normal controls.
DISCUSSION
Dystrophin transcripts in brain contain an alternative 5' terminal sequence from that found in muscle (16, 17) . We have isolated the genomic region encoding this alternative exon and have mapped this exon >90 kb upstream of the previously described muscle promoter. Thus, this exon cannot result from alternative splicing from the muscle promoter and must be transcribed from an alternative upstream promoter. We have mapped the 5' terminus of this alternative exon to within =30 bp by using PCR on human brain RNA. Using primer extension analysis on a transfected construct from this region, we have located two major transcriptional start sites within this 30 bp region and two minor start sites slightly further upstream. Although we cannot rule out that these sites are due to premature truncation by reverse transcriptase or artifactual initiation in the transfected construct, the close correspondence of the observed start sites with the PCR mapping of the endogenous transcripts suggest that the endogenous gene initiates transcription at these sites.
The magnitude of the spacing between promoters has several implications. The distance between the brain promoter and exon 2 represents the largest intron yet described (400 kb) and extends the total size of the gene to 2.4 million base pairs (40) . The upstream promoter region described here represents the extreme 5' terminus of the gene and may now be used to find polymorphic 5' flanking markers for linkage studies of the DMD gene. Linkage analysis is necessary for carrier detection and prenatal diagnosis in the one-third of DMD mutations that do not show detectable deletions of the DMD gene. The large distance between the promoters allows for one promoter to be disrupted without affecting the other in some individuals. In particular, it is expected that deletions may extend from far upstream ofthe DMD gene, a region that may be asymptomatically deleted, to breakpoints between the two promoters. Such deletions would result in individuals with normal muscle dystrophin that lack neuronal dystrophin. Due to the association of mental retardation with DMD, we predict that such deletions may be among the heterogeneous causes of X chromosome-linked mental retardation (reviewed in ref. 41) . A preliminary search for such patients has not yet been fruitful. However, like the mental retardation associated with DMD, it is expected that only one-third of such individuals with this deletion would be considered mentally retarded. It is also possible that the low level Medical Sciences: Boyce et al. 1 2 3 4 5 expression of the muscle promoter in the brain (16, 18) is sufficient for normal brain function in the absence ofthe brain promoter. Finally, it is interesting to note that one study of X chromosome-linked mental retardation has found suggestive evidence of linkage to the DMD gene (42) ; the use of the PCR analysis described here should resolve whether the mental retardation found in such families is due to deletion of the dystrophin brain promoter.
We have identified a patient with low levels of dystrophin in muscle and specific deletion of the downstream muscle promoter. Dystrophin transcription in this patient must therefore occur from an alternative promoter. Low levels of the brain transcript have been previously described in muscle cells (16, 18) . Thus, the dual promoters of dystrophin do not show absolute tissue specificity as their names currently in usage imply, and the use of more systematic names (P1 and P2) might be preferable. In any case, this low amount of the brain-type transcript might be sufficient to produce the reduced level of dystrophin observed in this patient. Alternatively, it is possible that a cryptic promoter is activated in this patient. Discrimination between these possibilities would require additional amounts of muscle biopsy material beyond that which we obtain for Western blot analysis. Nevertheless, it is hoped that the use of the probes described here for the upstream promoter may lead to better analyses in other patients with similar phenotypes.
Analysis of the promoter structure of the DMD gene has led to the prediction of individuals with tissue-specific promoter disruptions. In return, analysis of these patients may lead to insight into the function of this cytoskeletal gene. Such patients may be particularly critical for understanding the role of dystrophin in the brain, since analysis of the cognitive deficits ofDMD patients may be complicated by the decreased motor function of these individuals. Thus, identification of individuals with specific disruption of the brain promoter, using the probes described here, may ultimately shed light on the function of dystrophin in the human brain.
